{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=20", "query": { "condition": "Advanced Malignancy", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 9808, "total_pages": 981, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T16:49:38.462Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05932862", "title": "A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "XL309", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 429, "start_date": "2024-04-03", "completion_date": "2029-08-03", "has_results": false, "last_update_posted_date": "2025-09-05", "last_synced_at": "2026-11-01T16:49:38.462Z", "location_count": 16, "location_summary": "Fountain Valley, California • Jacksonville, Florida • Orlando, Florida + 12 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05932862" }, { "nct_id": "NCT01375842", "title": "A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors", "Hematologic Malignancies" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 661, "start_date": "2011-06-21", "completion_date": "2018-09-30", "has_results": false, "last_update_posted_date": "2018-12-11", "last_synced_at": "2026-11-01T16:49:38.462Z", "location_count": 16, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Stanford, California + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01375842" }, { "nct_id": "NCT00818441", "title": "Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-small Cell" ], "interventions": [ { "name": "Dacomitinib (PF-00299804)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 119, "start_date": "2009-03-11", "completion_date": "2015-04-30", "has_results": true, "last_update_posted_date": "2019-01-08", "last_synced_at": "2026-11-01T16:49:38.462Z", "location_count": 31, "location_summary": "Orange, California • Pleasant Hill, California • Salinas, California + 15 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Pleasant Hill", "state": "California" }, { "city": "Salinas", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00818441" }, { "nct_id": "NCT04592653", "title": "Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "Nemvaleukin alfa", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mural Oncology, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2020-09-30", "completion_date": "2024-12", "has_results": false, "last_update_posted_date": "2024-06-07", "last_synced_at": "2026-11-01T16:49:38.462Z", "location_count": 4, "location_summary": "Grand Rapids, Michigan • Houston, Texas • West Valley City, Utah + 1 more", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Houston", "state": "Texas" }, { "city": "West Valley City", "state": "Utah" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04592653" }, { "nct_id": "NCT07174661", "title": "Educational Tools for the Improvement of Early Advance Care Planning in Adolescents and Young Adults With Advanced Solid Tumors and High-Grade Brain Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Malignant Brain Neoplasm", "Recurrent Advanced Malignant Solid Neoplasm" ], "interventions": [ { "name": "Advance Care Planning", "type": "BEHAVIORAL" }, { "name": "Educational Intervention", "type": "OTHER" }, { "name": "Electronic Health Record Review", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 50, "start_date": "2025-09-02", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-11-01T16:49:38.462Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07174661" }, { "nct_id": "NCT01307956", "title": "Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Gastroesophageal Junction", "Esophageal Adenocarcinoma", "Stage IIA Esophageal Cancer", "Stage IIB Esophageal Cancer" ], "interventions": [ { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Panitumumab", "type": "BIOLOGICAL" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL", "RADIATION", "PROCEDURE" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 11, "start_date": "2011-02-28", "completion_date": "2015-12-23", "has_results": true, "last_update_posted_date": "2023-10-26", "last_synced_at": "2026-11-01T16:49:38.462Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01307956" }, { "nct_id": "NCT02420977", "title": "Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Advanced Prostate Cancer" ], "interventions": [ { "name": "Pelvic DCFPyL PET-MRI fusion or PET/MRI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 23, "start_date": "2018-12-06", "completion_date": "2025-03-01", "has_results": false, "last_update_posted_date": "2025-03-19", "last_synced_at": "2026-11-01T16:49:38.462Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02420977" }, { "nct_id": "NCT04837677", "title": "A Study of PRT1419 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Melanoma", "Lung Cancer", "Breast Cancer", "Esophageal Cancer", "Cervical Cancer", "Head and Neck Cancer" ], "interventions": [ { "name": "PRT1419", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prelude Therapeutics Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2021-08-11", "completion_date": "2023-02-06", "has_results": false, "last_update_posted_date": "2023-03-15", "last_synced_at": "2026-11-01T16:49:38.462Z", "location_count": 7, "location_summary": "Denver, Colorado • Lake Mary, Florida • Sarasota, Florida + 4 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04837677" }, { "nct_id": "NCT06840483", "title": "Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Zelenectide pevedotin (BT8009)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BicycleTx Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2025-03-03", "completion_date": "2028-12-30", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-11-01T16:49:38.462Z", "location_count": 8, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • St Louis, Missouri + 5 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06840483" }, { "nct_id": "NCT02722954", "title": "A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "Demcizumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoMed Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 29, "start_date": "2016-01", "completion_date": "2017-05-19", "has_results": false, "last_update_posted_date": "2020-08-11", "last_synced_at": "2026-11-01T16:49:38.462Z", "location_count": 5, "location_summary": "Denver, Colorado • Ann Arbor, Michigan • New York, New York + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02722954" } ] }